Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX140-B in type 2 diabetes mellitus with albuminuria
NL-OMON38004Phase 2Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing CCX140-B with Placebo (2 arms). Primary endpoints: Urinary albumin excretion and Safety and tolerability. Started Oct 2011; status: active, not recruiting.
02
Drugs
ilacirnon
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON38004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38004.